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Abstract
The ProteomeTools project builds molecular and digital tools from the human proteome to 
facilitate biomedical and life science research. Here, we report the generation and multimodal LC-
MS/MS analysis of >330,000 synthetic tryptic peptides representing essentially all canonical 
human gene products and exemplify the utility of this data. The resource will be extended to >1 
million peptides and all data will be shared with the community via ProteomicsDB and 
proteomeXchange.
Keywords
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Proteomic research greatly relies on the mass spectrometric and bioinformatic analysis of 
proteolytic digests of complex protein mixtures to infer protein identity and quantity1. Albeit 
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very powerful, there are technical and conceptual limitations in commonly followed 
approaches that make the measurement of complete proteomes very challenging. In part, this 
is due to the vast molecular complexity of proteomes that arises from e.g. gene expression, 
splicing of mRNAs or post-translational modification of proteins. As a result, the precise 
composition of a proteome is essentially always unknown. In addition, the measurement of 
protease digested proteomes by mass spectrometry creates large quantities of spectra of 
varying quality. The computational tools used in the field all make assumptions as to the 
presumed content of a proteome by matching mass spectra to peptides and to infer proteins. 
The statistical methods applied invariably represent compromises in terms of the sensitivity 
and specificity with which proteins are identified from complex mixtures. In analytical 
chemistry, verifying the identity of a molecule with certainty often makes use of synthetic 
reference standards. However, in proteome research the generation or use of such standards 
is only beginning to be implemented systematically2–4. To facilitate this, we have embarked 
on a project termed ProteomeTools (Fig. 1) in which we aim to synthesize ~1.4 million 
individual peptides to cover all human proteins. Here, we report on the synthesis and 
multimodal LC-MS/MS analysis of >330,000 synthetic tryptic peptides covering essentially 
all canonical human proteins as annotated in Swissprot. Peptides were chosen either based 
on their experimentally determined proteotypicity5, 6 or by brute force (all peptides within 
the typical mass range of a mass spectrometer) for hitherto unobserved proteins or those 
with little prior experimental evidence. We also included a subset of peptides of the Human 
SRMAtlas3 (Supplementary Table 1). As more data on the use of alternative proteases 
become available7, such peptides (~300,000) will be systematically incorporated into the 
project to increase spectral and sequence coverage for any given protein. Another 200,000 
peptides are earmarked for protein sequence variants such as protein isoforms or important 
natural or pathological variants. A substantial part (~350,000) of the capacity will be 
devoted to post-translationally modified peptides such as phosphorylation, acetylation, 
methylation, ubiquitinylation and mono-glycosylation8. While some of these peptides may 
be synthetically more challenging, their impact will likely be high as they represent the 
result of enzymatic activity that often modulates the function of proteins. Finally, we are 
reserving 200,000 peptides to represent other interesting biology such as disease associated 
mutations, HLA neo-antigens, protease cleavage products, small open reading frames or 
translated lincRNAs (Fig. 1a).
Tryptic peptides were individually synthesized, combined into pools of ~1,000 peptides and 
spiked with 66 non-naturally occurring and 15 stable isotope labeled peptides for retention 
time calibration. Whenever possible, we designed pools such that peptides do not have 
identical masses to avoid ambiguity in the mass spectrometric data or cover the entire LC 
gradient (Supplementary Figure 1). Each pool was subjected to an initial LC-MS/MS 
analysis using HCD and CID fragmentation on an Orbitrap Fusion Lumos mass 
spectrometer in order to determine which peptides were successfully synthesized, to 
determine their chromatographic retention times (RT) and compute retention time indices 
(iRT; Supplementary Figure 2)9. For each peptide pool, an inclusion list was generated to 
target peptides for fragmentation in further LC-MS experiments using five different 
fragmentation methods (HCD, CID, ETD, ETHCD, ETCID) with ion trap or Orbitrap 
readout and HCD spectra were recorded at 6 different collision energies (Supplementary 
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Figures 3–7). Peptides ranged from 7 to 40 amino acids in length and up to 96 % of these 
could be detected by LC-MS/MS in individual pools (78 % average recovery, 
Supplementary Figure 8–9). Using the open modification search option of MaxQuant/
Andromeda10, we were able to assess the side product profile to estimate the approximate 
yield of each peptide by measuring the percentage of the total MS signal that can be 
attributed to the target peptide sequence (Fig. 1b; Supplementary Figure 10). As expected, 
the purity of the synthesized peptides varied and many of the chemical by-products 
correspond to incompletely removed protection groups or missing amino acids. The 
presence of by-products turned out to be useful as truncated peptides provided additional 
evidence for the presence of the correct full length peptide. They may in the future also serve 
to refine retention time and fragmentation prediction or to identify some of the many good 
quality spectra that remain unidentified in typical proteomic experiments11.
One important goal of the project is to generate reference mass spectra for the identification 
and quantification of human peptides and proteins. At an arbitrarily high Andromeda score 
cut-off of 100, indicating very high spectral quality, we obtained a total of 11.3 million 
peptide spectrum matches (PSMs) mapping to 211,895 peptides and covering each gene by a 
median of 9 peptides (Fig. 1c). The median precursor intensity fraction (PIF; i.e. the fraction 
of the precursor signal vs. the total signal selected for fragmentation) was 92%, indicating 
that the spectra of most peptides are largely free of other contaminating peptides. Very high 
quality tandem mass spectra were obtained for all eleven tandem MS methods used but with 
varying degrees of proteome coverage. Analysis of the Andromeda search engine score 
distribution (Fig. 1d) showed that the 211,895 peptides (peptide FDR <0.002%) led to the 
identification of 19,735 of the 20,036 human genes deposited in Swissprot thus providing 
very high quality reference spectra for 98.5% of the human proteome (Supplementary Table 
2). The remaining genes/proteins often contain proline-rich repeats or retroviral sequences 
that cannot be covered by tryptic peptides of reasonable length. Some of these may 
eventually be covered when synthesizing peptides using other digestion enzyme 
specificities. As an interesting side note, because of considerable protein sequence 
conservation between the human and mouse proteomes, the peptide library also contains 
60,961 (proteotypic) peptides covering 12,599 (77%) unique mouse genes, thus considerably 
expanding the scope and utility of these peptides (Supplementary Table 3; Supplementary 
Notes).
One obvious use of synthetic peptide reference spectra is to confirm identifications of rarely 
(or newly) observed proteins. At the time of writing, there were only two spectra in 
ProteomicsDB supporting the identification of the same peptide of Aquaporin 12B with 
identification Q-scores different from the target-decoy distributions using the ‘picked’ 
target-decoy approach12 (Fig. 2a). The mirror plot showing the ion trap spectrum of the 
endogenous peptide and the corresponding spectrum of the synthetic peptide indicates very 
good agreement thus validating the identification of this protein from a single peptide.
We recorded HCD spectra at six different normalized collision energies with the aim to 
identify conditions for the measurement of peptides by targeted assays such as SRM, PRM 
or SWATH13, 14. To evaluate if HCD spectra obtained in this study are suitable for this 
purpose, we compared our data to ~9,000 peptides from a SWATH spectral library built from 
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proteome digests acquired on a QTOF instrument15. The analysis shows that there is very 
high correlation between the two types of data (R>0.9) and that spectra with poor correlation 
may represent false positives in the SWATH spectral library (Fig. 2b; Supplementary Figure 
11).
As an example to illustrate the usefulness of the data for developing software, we built a 
prototype classifier based on multiple HCD spectra for the same peptide at a particular 
collision energy. This classifier predicts the fragment ion intensity of tandem mass spectra of 
any peptide with Pearson correlation coefficients of around 0.9 (Fig. 2c, Supplementary 
Figures 12–14). Such tools may complement or eventually replace experimental data for the 
development of SRM/PRM/SWATH assays or facilitate the transfer of data recorded on a 
discovery proteomics instrument to an assay instrument. We consciously decided not to 
synthesize stable isotope encoded peptides for this project because their fragmentation 
spectra can be easily simulated based on spectra of the unlabeled version. It is also 
economically more efficient to create heavy peptides tailored to the project at hand. 
However, we are in the process of measuring peptides following chemical derivatization by 
tandem mass tags (TMT) and di-methyl labeling to cover the most commonly used stable 
isotope labeling methods.
An important aspect of the project is to enable and engage the proteomics community and 
this will be done in a number of ways. We encourage the community to propose sets of 
peptides to include in the project. Our stocks contain 100 clones of the peptide library which 
can be handed out to research groups willing to generate data on alternative mass 
spectrometric platforms such as QTOF instruments, ion mobility devices or different 
chromatographic systems. All of the current data is available in proteomeXchange and 
ProteomicsDB6, 16 and we will do the same for all upcoming data to engage the 
bioinformatics community to enable re-use and re-analysis of what we believe is a valuable 
resource.
The tryptic peptides reported here are only the beginning of the project and many further 
uses of the information generated can be envisaged. We plan to release new data every six 
months (~250,000 peptides per release) so that the community can access this data while the 
project progresses. As the physical reagents are finite resources, the long term value of the 
work lies in the data. It should be valuable for the development of software tools that may 
include intelligent data acquisition routines within the instrument control software17 or the 
development of more powerful database or spectral library search engines utilizing e.g. 
concepts of machine learning18. There is also still a need to develop improved statistical 
tools for the assessment of large-scale proteomic experiments particularly for data 
independent measurements such as SWATH or SRM/PRM. The spectral libraries generated 
in this project should provide ample opportunity to facilitate these applications19. Reagents 
and software aside, we also plan to build targeted assays in the next two years for sets of 
functionally important proteins such as kinases and phosphopeptides representing the 
activation status of signaling pathways. The results obtained so far demonstrate that the 
overall project is conceptually and technically feasible and yield scientifically meaningful 
and interesting results. We are therefore confident that the molecular and digital tools arising 
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from the ProteomeTools project will become a valuable resources for the proteomics 
community in the future.
Data availability
Reference spectra are available at https://www.proteomicsdb.org and updates to the resource 
are available at www.proteometools.org. The mass spectrometric data have been deposited 
with the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via 
the PRIDE partner repository with the dataset identifier PXD004732.
Online Methods
Synthetic peptide sets
To achieve extensive coverage of human proteins, three different sets of peptides were 
created or used in this study. First, a “proteotypic” peptide set covering confidently and 
frequently identified proteins was derived from prior mass-spectrometric evidence available 
in ProteomicsDB20, 21. We selected between 2 and 10 unique (at gene level) tryptic peptides 
for each human gene to reach a cumulative proteotypicity of ~95 % (i.e. we stopped 
selecting further peptides when the selected peptides covered at least 95% of all cases a 
particular protein was identified). Further constraints included a peptide length of 7 to 40 
amino acids and no more than two missed tryptic cleavage sites. The resulting list contained 
124,875 peptides covering 15,855 human Uniprot/SwissProt annotated genes. Second, a 
“missing proteome” set was constructed containing tryptic peptides mapping to genes which 
lacked confident experimental identification evidence in ProteomicsDB. Here, any gene-
unique tryptic peptide between 7 to 30 amino acids in length and allowing for a maximum of 
one missed cleavage site was included in the selection without restricting the number of 
peptides per gene. The resulting list contained 140,458 peptides covering 4,818 genes. 
Third, we obtained a subset of the “SRMAtlas” peptides comprising 90,967 peptides 
mapping to 19,099 genes also covering proteins with empirical evidence and “missing” 
proteins22. Altogether, the three sets of tryptic peptides contained 330,286 non-redundant 
peptides covering 19,840 human genes as annotated in Uniprot/SwissProt (Version 
2016-07-20; 42,164 protein sequences) (see Supplementary Table 1).
Peptide pool design
Peptide pools for synthesis and LC-MS measurement consisted of approximately 1,000 
peptides each. The peptide pools representing the “proteotypic” and “missing proteome” sets 
were designed to have a narrow peptide length distribution to support optimal synthesis. 
Near isobaric peptides (± 10 ppm) were distributed across different pools of similar length to 
avoid ambiguous masses in pools wherever possible (Supplementary Table 1). To this end, 
peptides were first ordered by length and mass. Second, the peptides were sorted by taking 
every nth peptide within the ordered list of peptides of one length, where n is the number of 
pools needed to distribute these peptides. The resulting ordering provided a well sampled 
sub-population of peptides with the same MW distribution. In a third step, peptides with 
near isobaric (± 10 ppm) mass were identified and, as long as no additional near isobaric 
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conflict was created, distributed across pools with similar peptide length (max 2 AAs 
difference).
The “SRMAtlas” peptide set was acquired in 96 well plates with each well containing one 
individual proteotypic peptide of 7–30 amino acids in length (i. e. one peptide per well, 
PEPotec Grade 1, suspended in 0.1% TFA in 50% (v/v) acetonitrile/water). These were also 
pooled into sets of approximately 1,000 peptides. To create plate pools, the peptides from 
every plate were first manually pooled together resulting in mixtures of 95 peptides (one 
quality control peptide present in each plate was discarded to avoid accumulation of this 
peptide in the subsequent pooling process). To create measurement pools of ~1,000 peptides, 
either 10 (for fully-tryptic peptides; i.e. C-terminal K/R) or 14 (non- and semi-tryptic 
peptides; i.e. non-K/R C-terminal) plate pools were combined. In order to avoid bias in 
pools of 1000 peptides regarding mass (MW) or hydrophobicity index (HI)23, the pooling 
scheme was computed to best mimic the overall MW and HI distribution of the entire set. 
We used the Kolmogorov-Smirnov test (KS-test) to quantify the distance of the MW and HI 
distribution between mixtures of plate pools to the total distribution of the total set. Starting 
with a plate pool or mixture of plate pools, all other (still available) plate pools were tested 
to generate a combined mixture that is closest to the overall set. The best match (lowest p-
value) was chosen and the process was repeated until the desired number of plate pools for 
combination was reached (Supplementary Figure 1). The resulting 96 measurement pools 
were desalted on C18 material (Waters, SepPak) before storage at -20 °C. All peptide 
sequences and their pool membership are listed in Supplementary Table 1.
Peptide synthesis
All peptides were individually synthesized following the Fmoc-based solid phase synthesis 
strategy. A carboxyamidomethylated cysteine building block was used to eliminate the need 
for cysteine modification prior to MS analysis. Peptides of the “proteotypic” and “missing 
gene” sets were synthesized by SPOT-synthesis on cellulose membranes at a scale of 
approximately 2–5 nmol of peptide per spot as described24. Depending on the length of 
peptides in a given pool, up to 6 peptide pools (containing at most 6,000 peptides; see 
Supplementary Notes) were synthesized in parallel using a purpose built peptide synthesizer. 
Five quality control peptides were synthesized along with every peptide pool. Peptides were 
cleaved from the membrane into pools of 1,000 peptides following the design criteria 
described above. Following solvent evaporation, peptides were stored at -20 °C until use. 
Peptides from the “SRMAtlas” set were synthesized in 96 well synthesizers (Thermo-Fisher 
Scientific, PEPotec Grade 1) at a scale of 0.1 mg per peptide. They were pooled and stored 
as described above.
Sample preparation for mass spectrometry
Dried peptide pools were initially solubilized in 100% DMSO to a concentration of 10 pmol/
μl by vortexing for 30 min at room temperature. The pools were then diluted to 10% DMSO 
using 1% formic acid in HPLC grade water to a stock solution concentration of 1 pmol/μl 
and stored at −20 °C until use. 10 μl of the stock solution were transferred to a 96-well plate 
and spiked with two retention time (RT) standards. The first set of retention time peptides 
(JPT Peptide Technologies) consisted of 66 peptides with non-naturally occurring peptide 
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sequences (Supplementary Table 1). 200 fmol per peptide was used per injection. The 
second RT standard (Pierce, Thermo Scientific) comprised 15 13C-labelled peptides and 100 
fmol per peptide was used per injection. Samples in the resulting 96-well plates were 
vacuum dried and stored at −20 °C until use.
Nanoscale liquid chromatography
For LC-MS analysis, the peptide pools in the 96 well plates were dissolved in 0.1% formic 
acid in water to a concentration of 100 fmol/μl per peptide (residual DMSO concentration of 
~1%). An estimated amount of 200 fmol of every peptide in a pool was subjected to liquid 
chromatography using a Dionex 3000 HPLC system (Thermo Fisher Scientific) using in-
house packed C18 columns. The setup consisted of a 75 μm × 2 cm trap column packed with 
5 μm particles of Reprosil Pur ODS-3 (Dr. Maisch GmbH) and a 75 μm × 40 cm analytical 
column, packed with 3 μm particles of C18 Reprosil Gold 120 (Dr. Maisch GmbH). Peptides 
were loaded onto the trap column using 0.1% FA in water. Separation of the peptides was 
performed by using a linear gradient from 4% to 35% ACN with 5% DMSO, 0.1% formic 
acid in water over 50 min followed by a washing step (60 min total method length) at a flow 
rate of 300 nL/min and a column temperature of 50 °C.
Mass spectrometry
The HPLC system was coupled on-line to an Orbitrap Fusion Lumos mass spectrometer 
(Thermo Fisher Scientific). Each peptide pool was first measured using a “survey method” 
consisting of an Orbitrap full MS scan (60k resolution, 5e5 AGC-target, 50 ms maximum 
injection time, 360–1300 m/z, profile mode), followed by MS2 events with a duty cycle of 2 
s for the most intense precursors and a dynamic exclusion set to 5 s as follows: (i) HCD scan 
with 28% normalized collision energy and Orbitrap readout (15k resolution, 1e5 AGC-
target, 22 ms maximum injection time, inject ions for all available parallelizable time 
enabled, 1.3 m/z isolation width, centroid mode); (ii) CID scan with 35% normalized 
collision energy and ion trap readout (rapid mode, 3e4 AGC target, 0.25 activation Q, 22 ms 
maximum injection time, inject ions for all available parallelizable time enabled, 1.3 m/z 
isolation width, centroid mode). From this data, inclusion lists with retention time 
constraints were generated for each pool and used for three subsequent LC-MS 
measurements focusing on different acquisition types. Precursors detected in the “survey 
method” were scheduled for fragmentation within a 5 min RT window. Peptides lacking 
identification in the survey run were added to the inclusion as 2+ or 3+ precursor ions, but 
without retention time scheduling. (1) The “HCD” method consisted of an Orbitrap MS1 
scan (120k resolution, 5e5 AGC-target, 50 ms maximum injection time, 360–1300 m/z, 
profile mode) followed by 3 seconds of MS2 scans with consecutive HCD scans at 20, 25 
and 30 normalized collision energy and Orbitrap readout (15k resolution, 1e5 AGC-target, 
20 ms maximum injection time, inject ions for all available parallelizable time enabled, 1.3 
m/z isolation width, centroid mode). (2) The “IT” method consisted of an Orbitrap MS1 
scan (120k resolution, 5e5 AGC-target, 50 ms maximum injection time, 360–1300 m/z, 
profile mode) followed by 3 seconds of MS2 scans with (i) CID scan with 35 normalized 
collision energy and ion trap readout (rapid mode, 3e4 AGC target, 0.25 activation Q, 20 ms 
maximum injection time, inject ions for all available parallelizable time enabled, 1.3 m/z 
isolation width, centroid mode); (ii) HCD scan with 28 normalized collision energy and ion 
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trap, (iii) HCD scan with 20 normalized collision energy and Orbitrap readout; (iv) HCD 
scan with 23 normalized collision energy and Orbitrap readout. (3) The “ETD” method 
consisted of an Orbitrap MS1 scan (120k resolution, 5e5 AGC-target, 50 ms maximum 
injection time, 360–1300 m/z, profile mode) followed by 3 seconds of MS2 scans with (i) 
ETD scan using charge dependent ETD parameters and Orbitrap readout25; (ii) EThcD scan 
using charge dependent ETD parameters and supplemental HCD activation with 28% 
normalized collision energy and Orbitrap readout; (iii) ETciD scan using charge dependent 
ETD parameters and supplemental CID activation with 35 normalized collision energy and 
Orbitrap readout with settings described above.
Data processing
The logistics of data processing and MS method generation was governed by an in-house 
database (Supplementary Figure 8). RAW data were analysed using MaxQuant version 
1.5.3.30 searching individual LC-MS runs against pool-specific databases (see 
Supplementary Table 2)26. If not mentioned otherwise, default parameters were used: 
Carbamidomethylated cysteine was specified as fixed modification, methionine oxidation as 
variable modification. First search tolerance was set to 20 ppm, main search tolerance to 4.5 
ppm and filtered for peptide and protein FDR of 1 %. Retention time windows of ±5 min 
were corrected for drifts using the internal retention time standards. The pool-specific 
inclusion lists were generated from confidently identified precursors (from the survey 
method) which passed an ad-hoc Andromeda score cut-off of 100. For analysis of synthesis 
side product, the survey MS run was searched with unspecific digestion and “dependent 
peptides” enabled.
Conserved peptide sequences in human and mouse
A current mouse protein sequence database representing 16,336 mouse genes was obtained 
from Swissprot (version dated 07/09/2016, 16,818 sequences). The database was in silico 
digested using tryptic cleavage specificity (no proline rule) and a maximum of 2 missed 
cleavages. The resulting peptide list was filtered for unique entries and mapped against our 
sequence list of peptides (see Supplementary Notes and Supplementary Table 3).
Comparison QTOF vs Fusion Lumos spectra
We systematically compared spectra generated in this project on an Orbitrap Fusion Lumos 
(Thermo) to a spectral library generated on a 5600 TripleTOF (QTOF) mass spectrometer 
(AB Sciex)27. For this, intensities of matching annotated fragment ions of the highest 
scoring (>100) beam-type CID spectrum per acquired normalized collision energy (Lumos) 
were correlated using Pearson correlation to the corresponding beam-type CID QTOF 
spectrum (acquired with rolling collision energy).
Fragmentation Prediction
First, MaxQuant result files were parsed and only spectra of unmodified doubly charged 
peptides with a PIF > 0.8 and a score of higher than 100 were selected for training. For each 
combination of amino acids N-terminal (left) and C-terminal (right) of the fragmentation 
position at a given normalized collision energy, a local polynomial regression (LOESS) 
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model was fitted using the peptide length normalized fragmentation position and the base 
peak intensity (BPI) normalized intensity of the y-ions (see Supplementary Figure 11–13). 
The resulting models were tested on pool 66 of the “proteotypic” set using the same peptide 
selection criteria. Each possible y-ion for each peptide passing the filters was predicted using 
the corresponding LOESS-fit. The predicted y-ion intensities were scored against the 
measured spectra using the Pearson correlation coefficient.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
AGC Automatic gain control
CE Collision energy
CID Collision induced dissociation
DIA Data independent acquisition
DMSO Dimethyl sulfoxide
ESI Electrospray ionization
ETciD Electron-transfer/collision induced dissociation
ETD Electron transfer dissociation
EThcD Electron-transfer/higher-energy collision dissociation
FA Formic acid
HCD Higher energy CID
HLA Human leucocyte antigen
IT IonTrap
iTRAQ Isobaric tags for relative and absolute quantification
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LC-MS/MS Liquid chromatography-tandem mass spectrometry
MS Mass spectrometry
NCE Normalized collision energy
nESI Nano-ESI
ORF Open reading frame
OT Orbitrap
PIF Precursor intensity fraction
QTOF Quadrupole time-of-flight
RT Retention time
SRM/PRM Selected reaction monitoring/parallel reaction monitoring
SWATH Sequential window acquisition of all theoretical fragment ion spectra
TMT Tandem mass tags
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Figure 1. Overview of the ProteomeTools project
(a) Planned segmentation of the 1.4 million peptides that will be selected from the human 
proteome and synthesized over the course of the project. Here, we report on the analysis of 
330,000 individually synthesized tryptic peptides. (b) Estimation of synthesis success using 
peptide precursor intensity information for the peptide SVSLLEER and its by-products. 
Here, 82% of the total MS signal can be attributed to the full length product. (c) Boxplots for 
the number of tandem mass spectra identifying a given peptide with very high confidence 
(Andromeda score >100; total of 11.3 million PSMs in 11 types of tandem MS); the number 
of such peptides (total of 211,895) covering a given protein/gene (total of 19,735) and the 
average precursor intensity fraction (PIF; see main text) of these peptides. (d) Distribution of 
peptide and protein identifications as a function of the Andromeda score. All data is 
available in ProteomicsDB and proteomeXchange.
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Figure 2. Data analysis and application
(a) Protein identification: target/decoy search results for the peptide 
LAAQGLGMQAACTLTR of Aquaporin 12B (AQP12B). There are only two spectra in 
ProteomicsDB with identification Q-Scores distinct from the decoy distribution (left panel). 
The inset shows the Q-Score distribution of all genes/proteins in ProteomicsDB, placing 
AQP12B well way from the decoy proteins. The right panel shows the best CID mass 
spectrum for AQP12B in ProteomicsDB (top) compared to the corresponding CID spectrum 
of the synthesized reference peptide confirming this identification. (b) Transferability 
between MS instruments: comparison of a spectrum acquired from a complex digest by 
beam-type CID on a QTOF instrument for the peptide VVSEDFLQDVSASTK compared to 
the corresponding spectrum of the synthesized reference peptide acquired by beam-type CID 
on an Orbitrap instrument (left panel). Fragment ion intensities show very high correlation 
(Pearson correlation of 0.9). Extending this analysis to ~9,000 peptides confirmed the high 
correlation of these two types of tandem mass spectra (right panel). (c) Development of a 
predictor for tandem mass spectra. HCD data were recorded at six collision energies. The 
left panel shows the median relative fragment ion intensities of 12 y-fragment ions for the 
peptide YYLIQLLEDDAQR. Using these characteristics for all spectra of all peptides, a 
predictive model was trained for each normalized collision energy. The comparison of 
measured and predicted spectra for YYLIQLLEDDAQR (middle panel) show very good 
agreement. The histogram on the right shows that the predictor (tested on 529 peptide 
sequences and 3,248 spectra) of pool 66 of the proteotypic peptide set, is generally able to 
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predict the relative y-ion intensity for a given peptide with good quality (see Supplementary 
Notes for details).
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